The role of cannabinoid transmission in emotional memory formation: Implications for addiction and schizophrenia

Frontiers in Psychiatry

Volumn 5, Issue JUN, 2014, Pages

  Tan, Huibing ^a   Ahmad, Tasha ^a   Loureiro, Michael ^a   Zunder, Jordan ^a   Laviolette, Steven R ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Addiction; Amygdala; Cannabinoids; Dopamine; Emotion; Frontal cortex; Opiates; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID;

ADDICTION; BASOLATERAL AMYGDALA; COMORBIDITY; EMOTIONALITY; HUMAN; LIMBIC CORTEX; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEDIAL PREFRONTAL CORTEX; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROTRANSMISSION; PREFRONTAL CORTEX; REVIEW; REWARD; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84904501557     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00073     Document Type: Review

References (99)

1. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 83:393-411. doi: 10.1016/S0306-4522(97)00436-3
2. McDonald AJ, Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience (2001) 107:641-52. doi:10.1016/S0306-4522(01)00380-3
3. Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol (2014) 16(29C):1-8. doi:10.1016/j.conb.2014.03.017
4. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol (2008) 184:435-77. doi:10.1007/978-3-540-74805-2_14
5. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci (1990) 87:1932-6. doi:10.1073/pnas.87.5.1932
6. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, et al. Distribution of CB1 receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 21:9506-18.
7. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1 and non-CB1-mediated actions. Neuropharmacology (2004) 46:115-25. doi:10.1016/j.neuropharm.2003.08.003
8. Tan H, Lauzon NM, Bishop SF, Bechard MA, Laviolette SR. Integrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encoding. Cereb Cortex (2010) 20:1486-96. doi:10.1093/cercor/bhp210
9. Tan H, Lauzon NM, Bishop SF, Chi N, Bechard M, Laviolette SR. Cannabinoid transmission in the basolateral amygdala modulates fear memory formation via functional inputs to the prelimbic cortex. J Neurosci (2012) 31:5300-12. doi:10.1523/JNEUROSCI.4718-10.2011
10. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology (2008) 33:473-9. doi:10.1038/sj.npp.1301437
11. Deserno L, Boehme R, Heinz A, Schlagenhauf F. Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group? Front Psychiatry (2013) 4:172. doi:10.3389/fpsyt.2013.00172
12. Terrett G, McLennan SN, Henry JD, Biernacki K, Mercuri K, Curran HV, et al. Prospective memory impairment in long-term opiate users. Psychopharmacology (2014) 231(13):2623-32. doi:10.1007/s00213-014-3432-6
13. Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend (2006) 84:240-7. doi:10.1016/j.drugalcdep.2006.02.006
14. Mesholam-Gately RI, Gibson LE, Seidman LJ, Green AI. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophr Res (2014) 155(1-3):45-51. doi:10.1016/j.schres.2014.03.002
15. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry (1999) 6:287-96.
16. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (2007) 187:222-8. doi:10.1007/s00213-006-0405-4
17. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry (2008) 13:267-76.
18. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet (1987) 26:1483-6. doi:10.1016/S0140-6736(87)92620-1
19. Andréasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand (1989) 79:505-10. doi:10.1111/j.1600-0447.1989.tb10296.x
20. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport (1999) 10:1665-9. doi:10.1097/00001756-199906030-00008
21. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Neatby MA, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 94:29-36.
22. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 29:2108-14. doi:10.1038/sj.npp.1300558
23. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 194:371-2. doi:10.1192/bjp.bp.108.053843
24. Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res (2013) 148:145-50. doi:10.1016/j.schres.2013.06.013
25. Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology (2011) 36:1620-30. doi:10.1038/npp.2011.43
26. Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, et al. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res (2012) 141:185-8. doi:10.1016/j.schres.2012.07.021
27. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28:355-60. doi:10.1016/j.pnpbp.2003.11.005
28. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry (2007) 62:616-26. doi:10.1016/j.biopsych.2006.12.004
29. Scherma M, Fadda P, Le Foll B, Forget B, Fratta W, Goldberg SR, et al. The endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets (2008) 7:468-81. doi:10.2174/187152708786927859
30. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J (2006) 6:126-30. doi:10.1038/sj.tpj.6500352
31. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet (2006) 120:581-8. doi:10.1007/s00439-006-0250-x
32. Maroun M. Stress reverses plasticity in the pathway projecting from the ventromedial prefrontal cortex to the basolateral amygdala. Eur J Neurosci (2006) 24(10):2917-22. doi:10.1111/j.1460-9568.2006.05169.x
33. Richter-Levin G, Maroun M. Stress and amygdala suppression of metaplasticity in the medial prefrontal cortex. Cereb Cortex (2010) 20:2433-41. doi:10.1093/cercor/bhp311
34. Laviolette SR, Lipski WJ, Grace AA. A sub-population of neurons in the medial prefrontal cortex encodes emotional learning through burst and frequency codes through a dopamine D4 receptor-dependent basolateral amygdala in-put. J Neurosci (2005) 25:6066-75. doi:10.1523/JNEUROSCI.1168-05.2005
35. Rosenkranz JA, Grace AA. Dopamine-mediated modulation of odour-evoked amygdala potentials during Pavlovian conditioning. Nature (2002) 417:282-7. doi:10.1038/417282a
36. Lauzon NM, Bishop SF, Laviolette SR. Dopamine D1 versus D4 receptors differentially modulate the encoding of salient versus nonsalient emotional information in the medial prefrontal cortex. J Neurosci (2009) 29:4836-45. doi:10.1523/JNEUROSCI.0178-09.2009
37. Rosenkranz JA, Grace AA. Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats. J Neurosci (2001) 21:4090-103.
38. Laviolette SR, Grace AA. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J Neurosci (2006) 26:6458-68. doi:10.1523/JNEUROSCI.0707-06.2006
39. Maroun M, Richter-Levin G. Exposure to acute stress blocks the induction of long-term potentiation of the amygdala-prefrontal cortex pathway in vivo. J Neurosci (2003) 23:4406-9.
40. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci (1999) 11:4213-25. doi:10.1046/j.1460-9568.1999.00847.x
41. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci (2006) 26:5794-9. doi:10.1523/JNEUROSCI.0372-06.2006
42. Cass DK, Flores-Barrera E, Thomases DR, Vital WF, Caballero A, Tseng KY. CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry (2014) 19(5):536-43. doi:10.1038/mp.2014.14
43. Rea K, Olango WM, Harhen B, Kerr DM, Galligan R, Fitzgerald S, et al. Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. Pain (2013) 154:576-85. doi:10.1016/j.pain.2012.12.021
44. Pistis M, Muntoni AL, Pillolla G, Gessa GL. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci (2002) 15:1795-802. doi:10.1046/j.1460-9568.2002.02019.x
45. Pistis M, Porcu G, Melis M, Diana M, Gessa GL. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci (2001) 14:96-102. doi:10.1046/j.0953-816x.2001.01612.x
46. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci (2002) 15:2057-61. doi:10.1046/j.1460-9568.2002.02041.x
47. Lintas A, Chi N, Lauzon NM, Bishop SF, Sun N, Tan H, et al. Inputs from the basolateral amygdala to the nucleus accumbens shell control opiate reward magnitude via differential dopamine D1 or D2 receptor transmission. Eur J Neurosci (2012) 35:279-90. doi:10.1111/j.1460-9568.2011.07943.x
48. Bishop SF, Lauzon NM, Bechard M, Gholizadeh S, Laviolette SR. NMDA receptor hypofunction in the prelimbic cortex increases sensitivity to the rewarding properties of opiates via dopaminergic and amygdalar substrates. Cereb Cortex (2011) 21:68-80. doi:10.1093/cercor/bhq060
49. Sun N, Laviolette SR. Inactivation of the basolateral amygdala during opiate reward learning disinhibits prelimbic cortical neurons and modulates associative memory extinction. Psychopharmacology (2013) 222:645-61. doi:10.1007/s00213-012-2665-5
50. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem (2003) 10:116-28. doi:10.1101/lm.53303
51. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci (2004) 24:9953-61. doi:10.1523/JNEUROSCI.2134-04.2004
52. Kosaka H, Omori M, Murata T, Iidaka T, Yamada H, Okada T, et al. Differential amygdala response during facial recognition in patients with schizophrenia: an fMRI study. Schizophr Res (2002) 57:87-95. doi:10.1016/S0920-9964(01)00324-3
53. Rauch AV, Reker M, Ohrmann P, Pedersen A, Bauer J, Dannlowski U, et al. Increased amygdala activation during automatic processing of facial emotion in schizophrenia. Psychiatry Res (2010) 182:200-6. doi:10.1016/j.pscychresns.2010.03.005
54. Marwick K, Hall J. Social cognition in schizophrenia: a review of face processing. Br Med Bull (2008) 88:43-58. doi:10.1093/bmb/ldn035
55. van Erp TG, Greve DN, Rasmussen J, Turner J, Calhoun VD, Young S, et al. A multi-scanner study of subcortical brain volume abnormalities in schizophrenia. Psychiatry Res (2014) 222(1-2):10-6. doi:10.1016/j.pscychresns.2014.02.011
56. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry (2006) 63:139-49. doi:10.1001/archpsyc.63.2.139
57. Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL, et al. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A (2009) 106:4888-93. doi:10.1073/pnas.0900835106
58. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology (2009) 34:2733-45. doi:10.1038/npp.2009.114
59. Lee TT, Hill MN. Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB1 receptor binding in male rats. Neuroscience (2013) 26(249):106-14. doi:10.1016/j.neuroscience.2012.11.017
60. Auclair N, Otani S, Soubrié P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol (2000) 83:3287-95.
61. Abush H, Akirav I. Cannabinoids modulate hippocampal memory and plasticity. Hippocampus (2010) 20:1126-38. doi:10.1002/hipo.20711
62. Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci (1999) 19:6795-805.
63. Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry (2004) 161:480-9. doi:10.1176/appi.ajp.161.3.480
64. Cossu G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res (2001) 118:61-5. doi:10.1016/S0166-4328(00)00311-9
65. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 283:401-4. doi:10.1126/science.283.5400.401
66. Laviolette SR, Gallegos RA, Henriksen SJ, van der Kooy D. Opiate state controls bi-directional reward signaling via GABAA receptors in the ventral tegmental area. Nat Neurosci (2004) 7:160-9. doi:10.1038/nn1182
67. Nader K, van der Kooy D. Deprivation state switches the neurobiological substrates mediating opiate reward in the ventral tegmental area. J Neurosci (1997) 17:383-90.
68. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci (2004) 19:3183-92. doi:10.1111/j.0953-816X.2004.03420.x
69. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 30:2046-57. doi:10.1038/sj.npp.1300754
70. Cheer JF, Wassum KM, Heien MLAV, Phillips PEM, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci (2004) 24:4393-400. doi:10.1523/JNEUROSCI.0529-04.2004
71. Sperlágh B, Windisch K, Andó RD, Sylvester Vizi E. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int (2009) 54:452-7. doi:10.1016/j.neuint.2009.01.017
72. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport (1997) 8:649-52. doi:10.1097/00001756-199702100-00014
73. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology (2007) 32:607-15. doi:10.1038/sj.npp.1301127
74. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu opioid receptor mechanism. Science (1997) 276:2048-50. doi:10.1126/science.276.5321.2048
75. Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry (2012) 72:803-10. doi:10.1016/j.biopsych.2012.04.026
76. Sun N, Chi N, Lauzon N, Bishop S, Tan H, Laviolette SR. Acquisition, extinction, and recall of opiate reward memory are signaled by dynamic neuronal activity patterns in the prefrontal cortex. Cereb Cortex (2011) 21:2665-80. doi:10.1093/cercor/bhr031
77. De Jaeger X, Bishop SF, Ahmad T, Lyons D, Ng GA, Laviolette SR. The effects of AMPA receptor blockade in the prelimbic cortex on systemic and ventral tegmental area opiate reward sensitivity. Psychopharmacology (2013) 225:687-95. doi:10.1007/s00213-012-2852-4
78. Ahmad T, Lauzon NM, de Jaeger X, Laviolette SR. Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus μ-opiate receptor dependent mechanisms. J Neurosci (2013) 33:15642-51. doi:10.1523/JNEUROSCI.1686-13.2013
79. Bechara A, Zito KA, van der Kooy D. Peripheral receptors mediate the aversive conditioning effects of morphine in the rat. Pharmacol Biochem Behav (1987) 28:219-25. doi:10.1016/0091-3057(87)90218-8
80. Bechara A, van der Kooy D. Kappa receptors mediate the peripheral aversive effects of opiates. Pharmacol Biochem Behav (1987) 28:227-33. doi:10.1016/0091-3057(87)90218-8
81. Davis CM, Rice KC, Riley AL. Opiate-agonist induced taste aversion learning in the Fischer 344 and Lewis inbred rat strains: evidence for differential mu opioid receptor activation. Pharmacol Biochem Behav (2009) 93:397-405. doi:10.1016/j.pbb.2009.06.001
82. Johnson S, North R. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci (1992) 12:483-8.
83. Gysling K, Wang RY. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res (1983) 277:119-27. doi:10.1016/0006-8993(83)90913-7
84. Margolis EB, Hjelmstad GO, Bonci A, Fields HL. κ-Opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci (2003) 23:9981-6.
85. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A (2006) 103:2938-42. doi:10.1073/pnas.0511159103
86. Ford CP. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci (2006) 26:2788-97. doi:10.1523/JNEUROSCI.4331-05.2006
87. Tan H, Bishop SF, Lauzon NM, Sun N, Laviolette SR. Chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. Neuropharmacology (2009) 56:741-51. doi:10.1016/j.neuropharm.2008.12.008
88. Laviolette SR, van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry (2003) 8:50-9.
89. Lintas A, Chi N, Lauzon NM, Bishop SF, Gholizadeh S, Sun N, et al. Identification of a dopamine receptor-mediated opiate reward memory switch in the basolateral amygdala-nucleus accumbens circuit. J Neurosci (2011) 31:11172-83. doi:10.1523/JNEUROSCI.1781-11.2011
90. Katsidoni V, Kastellakis A, Panagis G. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol (2013) 16:2273-84. doi:10.1017/S1461145713000709
91. Hernandez G, Cheer JF. Effect of CB1 receptor blockade on food-reinforced responding and associated nucleus accumbens neuronal activity in rats. J Neurosci (2012) 32:11467-77. doi:10.1523/JNEUROSCI.1833-12.2012
92. Sellings LH, Baharnouri G, McQuade LE, Clarke PB. Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. Eur J Neurosci (2008) 28:342-52. doi:10.1111/j.1460-9568.2008.06341.x
93. Lyons D, de Jaeger X, Rosen LG, Ahmad T, Lauzon NM, Zunder J, et al. Opiate exposure and withdrawal induces a molecular memory switch in the basolateral amygdala between ERK1/2 and CaMKIIα-dependent signaling substrates. J Neurosci (2013) 33:14693-704. doi:10.1523/JNEUROSCI.1226-13.2013
94. Sáez-Cassanelli JL, Fontanella GH, Delgado-García JM, Carrión AM. Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia. J Neurochem (2007) 103:2629-39. doi:10.1111/j.1471-4159.2007.05000.x
95. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 50:71-83. doi:10.1016/S0006-3223(01)01134-9
96. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience (2001) 103:9-15. doi:10.1016/S0306-4522(00)00552-2
97. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry (2014) 75:470-8. doi:10.1016/j.biopsych.2013.05.027
98. Urban NBL, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, et al. Dopamine release in chronic cannabis users: a [11C]raclopride positron emission tomography study. Biol Psychiatry (2012) 71:677-83. doi:10.1016/j.biopsych.2011.12.018
99. Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend (2012) 128:52-7. doi:10.1016/j.drugalcdep.2012.07.016